CRBP News and Press, Corbus Pharmaceuticals Holdings Inc. From 01/31/24

NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 sh...

2024-01-31 01:47:00 ET More on Corbus Pharmaceuticals Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds Corbus Pharma reverses gains on common stock offering Corbus P...

NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or,...

2024-01-30 11:50:46 ET Gainers: Neximmune ( NEXI ) +163% . Pixelworks ( PXLW ) +47% . PepGen ( PEPG ) +37% . Rail Vision Ltd ( RVSN ) +36% . Bit Origin Ltd ( BTOG ) +34% . Vivos Therapeutics ( VVOS ) +32% . GRI Bi...

2024-01-30 07:13:44 ET Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patie...

2024-01-29 14:17:45 ET Summary Corbus Pharmaceuticals has experienced a surge in stock price after positive clinical results for their antibody drug conjugate, CRB-701. CRBP is conducting phase 1 studies for CRB-701 in patients with Nectin-4-positive solid tumors, showing favorabl...

2024-01-29 09:00:03 ET More on Corbus Pharmaceuticals Corbus Pharma surges after early Phase 1 data for tumor candidate Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for...

2024-01-29 08:22:54 ET Losers: Panbela Therapeutics PBLA -63% on $9M public offering . Aclarion ( ACON ) -19% . Corbus Pharmaceuticals Holdings ( CRBP ) -21% it releases data for ADC Tumor candidate . Richtech Robotics ( RR ) -11% . ...

2024-01-29 07:18:08 ET The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29. CRBP was previously trading at a meagre valuation below $7. Despite the st...

--News Direct-- New York, Jan. 29, 2024 - ( Plato Data ) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December d...